Zealand Pharma A/S | Ownership
Companies that own Zealand Pharma A/S
Wellington Management Co. LLP
1,557,307
5.05%
-542,496
0%
01/03/2018
Royce & Associates LP
1,534,556
4.99%
336,006
0.13%
01/15/2018
Fidelity Management & Research Co.
400,644
1.3%
-112,234
0%
07/31/2018
Edmond de Rothschild Asset Management (France) SA
305,000
0.99%
-25,000
0.05%
03/31/2018
Teton Advisors, Inc. (Investment Management)
300,000
0.98%
0
0.35%
06/30/2018
Banque Internationale À Luxembourg SA (Denmark)
264,291
0.86%
264,291
5.09%
06/30/2017
Dimensional Fund Advisors LP
213,490
0.69%
27,807
0%
04/30/2018
Norges Bank Investment Management
186,605
0.61%
16,802
0%
12/31/2017
Apo Asset Management GmbH
166,605
0.54%
71,850
0.1%
06/29/2018
BlackRock Fund Advisors
147,147
0.48%
1,426
0%
09/06/2018
| Address |
Smedeland 36
Glostrup ZE 2600
Denmark
|
|
Employees
|
- |
| Website |
http://www.zealandpharma.com |
| Updated |
07/08/2019 |
| Zealand Pharma A/S is a biotechnology company that engages in the discovery, design, and development of peptide based medicines. Its products include Soliqua and Lyxumia. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Glostrup, Denmark. |
